Drospirenone EP Impurity I 新品

Drospirenone EP Impurity I is chemically 7β-(Hydroxymethyl)-15α,16α-dihydro-3′H-cyclopropa[15,16]-17α-pregna-3,5-diene-21,17-carbolactone (as per EP) ; 17-Hydroxy-7β-hydroxymethyl-15β,16β-methylene-17α-pregn-3,5(6)-diene-21-carboxylic acid, γ-lactone (as per USP). It is also known as 7β-Hydroxymethyldiene Drospirenone (EP) ; 7-Hydroxymethyl 3,5(6)-diene drospirenone (USP). Drospirenone EP Impurity I is supplied with detailed characterization data compliant with regulatory guideline. Drospirenone EP Impurity I can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Drospirenone.

祥根生物医药于2008年12月成立，是一家集药物研发、生产、销售的创新型医药高科技企业，荣获“国家高新技术企业”和“博士后实践创新基地”等称号。祥根生物医药拥有药物成分标准物质、关键中间体、原料药与药品进出口全产业链平台。祥根是众多全球知名标准品（Aozeal/USP/EP/LGC/Bachem/TLC/TRC/意大利试剂等）和原料药（INKE/Bachem/瑞迪/意迪那等）总代理和授权代理商，处于行业领先水平。 祥根生物医药拥有一个尊重人才、重视绩效、持续创新的平台。 研发团队由多名海外高层次人才领衔，研发人员50余人；获得相关发明专利30余项。祥根生物医药的企业责任是：回报员工、回报合作伙伴、回报社会；企业愿景是：提升药品质量，保护人类健康。